James Quigley
Stock Analyst at Morgan Stanley
(1.77)
# 3,244
Out of 5,124 analysts
25
Total ratings
50%
Success rate
2.49%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $77.81 | +63.22% | 7 | Dec 9, 2025 | |
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $50.88 | +6.13% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $137.87 | -14.41% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $48.46 | +34.13% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $9.35 | +12.30% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $32.68 | +22.40% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.08 | +419.48% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $77.81
Upside: +63.22%
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $50.88
Upside: +6.13%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $137.87
Upside: -14.41%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $48.46
Upside: +34.13%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.35
Upside: +12.30%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $32.68
Upside: +22.40%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.08
Upside: +419.48%